Megan Hollasch
Articles
December 1st 2024
Tislelizumab Pushes HCC Field Forward With 2024 NCCN Guideline Category 1 Recommendation
Tislelizumab's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for hepatocellular carcinoma (HCC) as a category 1 recommendation marks an advancement in the treatment landscape for HCC.
August 28th 2023
HER2 Amplification Shows Prognostic Capabilities in mCRC
Although HER2 amplification showed prognostic capabilities in patients with RAS wild-type metastatic colorectal cancer (mCRC), it was not predictive of survival benefit as a first-line treatment option in combination with panitumumab vs standard-of-care bevacizumab.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: December 17th 2024 | Updated: December 22nd 2024
ICYMI: Highlights From IMS 2024
